Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 8.4% – Should You Buy?

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) traded up 8.4% during mid-day trading on Wednesday . The company traded as high as $18.65 and last traded at $18.6750. Approximately 536,130 shares were traded during trading, a decline of 75% from the average session volume of 2,144,357 shares. The stock had previously closed at $17.23.

Wall Street Analyst Weigh In

Several brokerages have commented on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley decreased their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. JPMorgan Chase & Co. lowered their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.33.

Adaptive Biotechnologies Price Performance

The stock has a market cap of $3.24 billion, a PE ratio of -61.36 and a beta of 2.15. The business has a fifty day moving average of $15.24 and a 200-day moving average of $15.61.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the business posted ($0.20) EPS. As a group, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 30,941 shares of the company’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $14.83, for a total value of $458,855.03. Following the completion of the sale, the chief operating officer directly owned 434,188 shares of the company’s stock, valued at $6,439,008.04. This represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 100,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $17.37, for a total transaction of $1,737,000.00. Following the transaction, the insider owned 1,412,058 shares in the company, valued at approximately $24,527,447.46. The trade was a 6.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 551,574 shares of company stock worth $8,427,395 over the last quarter. 5.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several large investors have recently modified their holdings of ADPT. AQR Capital Management LLC boosted its stake in shares of Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after buying an additional 2,914 shares in the last quarter. Caxton Associates LLP purchased a new stake in Adaptive Biotechnologies during the first quarter worth $93,000. New York State Common Retirement Fund lifted its holdings in Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after buying an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in Adaptive Biotechnologies by 728.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after acquiring an additional 333,379 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.